%0 Journal Article
%A Haist, Maximilian
%A Stege, Henner
%A Rogall, Friederike
%A Tan, Yuqi
%A von Wasielewski, Imke
%A Klespe, Kai Christian
%A Meier, Friedegund
%A Mohr, Peter
%A Kähler, Katharina C
%A Weichenthal, Michael
%A Hauschild, Axel
%A Schadendorf, Dirk
%A Ugurel, Selma
%A Lodde, Georg
%A Zimmer, Lisa
%A Gutzmer, Ralf
%A Debus, Dirk
%A Schilling, Bastian
%A Kreuter, Alexander
%A Ulrich, Jens
%A Meiss, Frank
%A Herbst, Rudolf
%A Forschner, Andrea
%A Leiter, Ulrike
%A Pfoehler, Claudia
%A Kaatz, Martin
%A Ziller, Fabian
%A Hassel, Jessica C
%A Tronnier, Michael
%A Sachse, Michael
%A Dippel, Edgar
%A Terheyden, Patrick
%A Berking, Carola
%A Heppt, Markus V
%A Kiecker, Felix
%A Haferkamp, Sebastian
%A Gebhardt, Christoffer
%A Simon, Jan Christoph
%A Grabbe, Stephan
%A Loquai, Carmen
%T Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG.
%J Journal for ImmunoTherapy of Cancer
%V 11
%N 9
%@ 2051-1426
%C London
%I BioMed Central
%M DKFZ-2023-01906
%P e007630
%D 2023
%X Adjuvant therapy with immune-checkpoint inhibitors (CPI) or BRAF/MEK-directed targeted therapy (TT) improves recurrence-free survival (RFS) for patients with advanced, BRAFV600-mutant (BRAFmut) resected melanoma. However, 40
%K Adjuvant Drug Therapy (Other)
%K Immune Checkpoint Inhibitors (Other)
%K Melanoma (Other)
%K Molecular Targeted Therapy (Other)
%K Recurrence (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37730278
%R 10.1136/jitc-2023-007630
%U https://inrepo02.dkfz.de/record/282917